Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.

Abstract

A 33-year-old male presenting with subacute abdominal pain was found to have hyperbilirubinaemia, hypokalaemia and hyponatraemia. This was in the setting of transitioning between deferasirox iron chelator formulations, from dispersible tablets to film-coated tablets for ongoing treatment of chronic iron overload secondary to transfusion requirement for beta-thalassemia major. A liver biopsy demonstrated acute cholestasis with patchy confluent hepatocellular necrosis and mild to moderate microvesicular steatosis. Based on the histological, biochemical and clinical findings, the diagnosis of hepatotoxicity and Fanconi-like syndrome was made. The patient improved clinically and biochemically with cessation of the deferasirox film-coated tablets and supportive management. To our knowledge, this is the first case report of hepatotoxicity and Fanconi-like syndrome occurring due to deferasirox film-coated tablets with previous tolerance of dispersible deferasirox tablets. It is important to raise clinical awareness of this potentially severe complication.

• Authors: Jacqueline Fraser, Rowena Brook, Tony He, Diana Lewis
• Journal: BMJ case reports (BMJ Case Rep) Vol. 13 Issue 7 (Jul 09 2020) ISSN: 1757-790X [Electronic] England
• PMID: 32646935 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Iron Chelating Agents
• Deferasirox

Topics

• Adult
• Chemical and Drug Induced Liver Injury, Chronic (etiology, therapy)
• Deferasirox (adverse effects)
• Fanconi Syndrome (chemically induced, therapy)
• Humans
• Iron Chelating Agents (adverse effects)
• Male
• beta-Thalassemia (drug therapy)